Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 32,733 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Comparator: Placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
View directory record Official record
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NCT00745030
View directory record Official record
Conditions
REM Behavior Disorder, Parkinsonism
Interventions
Rozerem, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 2, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

NCT05289830
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Periampullary Cancer
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke

NCT07813130
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
AB126 Neural Exosomes Intravenous Injection, AB126 Placebo
Biological · Other
Lead sponsor
Aruna Bio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Active, not recruiting Early Phase 1 Interventional

Targeting Drug Memories With Methylphenidate

NCT05978167
View directory record Official record
Conditions
Substance Use Disorder, Cocaine Use Disorder
Interventions
Methylphenidate, Memory reconsolidation, Placebo
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
26 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Adult Participants With Schizophrenia

NCT07410507
View directory record Official record
Conditions
Schizophrenia
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
32
States / cities
Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 2, 2026, 9:14 AM EDT
Withdrawn Phase 4 Interventional

A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs

NCT06708611
View directory record Official record
Conditions
Heart Failure
Interventions
torsemide
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

NCT06721871
View directory record Official record
Conditions
Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Interventions
Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971
View directory record Official record
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Bioavailability of IV and SC LBR-101

NCT01991509
View directory record Official record
Conditions
Bioavailability and Pharmacokinetics
Interventions
LBR-101 IV, LBR-101 SC
Biological
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional

Premedication With Melatonin in Lumbar Medial Branch Block Procedure

NCT02415309
View directory record Official record
Conditions
Anxiety
Interventions
2 mg Melatonin, 10mg Melatonin, Placebo
Drug · Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Diego, California • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

NCT04622332
View directory record Official record
Conditions
Corona Virus Infection
Interventions
SIR1-365, Matching Placebo
Drug
Lead sponsor
Sironax USA, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
West Palm Beach, Florida • Peoria, Illinois • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

NCT01879332
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, BIA 2-093 3000 mg once daily, BIA 2-093 3600 mg once daily
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional

Investigation of Cycloserine as a Smoking Cessation Treatment

NCT01062932
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

One Week Clinical Study in Subjects With Menopausal Symptoms

NCT06794021
View directory record Official record
Conditions
Healthy, Menopause
Interventions
Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo
Dietary Supplement · Other
Lead sponsor
Olly, PBC
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Aromatherapy to Reduce Pain and Anxiety During Cervical Colposcopy

NCT01214304
View directory record Official record
Conditions
Colposcopy
Interventions
Essential Lavender Oil, Lavender Scent
Other
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older · Female only
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Collagen Vitamin C Dose Response Performance

NCT03293004
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Hydrolyzed collagen, Vitamin C, Optimized Hydrolyzed Collagen and Vitamin C, Gummy Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People

NCT00099645
View directory record Official record
Conditions
HIV Infections
Interventions
Mifepristone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
10
States / cities
Torrance, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 9:14 AM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 2, 2026, 9:14 AM EDT